Therapeutic Effects of a New "Indigenous Vaccine" Developed Using Novel Native "Indian Bison Type" Genotype of Mycobacterium avium Subspecies paratuberculosis for the Control of Clinical Johne's Disease in Naturally Infected Goatherds in India.
Therapeutic efficacy of an "Indigenous vaccine" has been evaluated with respect to a commercial vaccine (Gudair, Spain), for the control of clinical Johne's disease (JD) in naturally infected goatherds. Seventy-one goats (JD positive) were randomly divided into 3 groups ("Bison", "Gudair" and "Sham-immunized"). After vaccination, goats were monitored for physical condition, morbidity, mortality, body weights, shedding of M. paratuberculosis (MAP) in feces, internal condition and lesions, as well as humoral and cell-mediated immune responses for 210 days. Study showed marked overall improvement in physical condition of vaccinated goats and average body weight gain was significantly higher (P < .05) in "Bison" group as compared to "Sham-immunized" goats. Mortality due to JD was significantly (P < .05) lower in vaccinated groups than in "sham-immunized". Morbidity rates (due to diarrhea and weakness) were lower in "Bison" group as compared to other groups. Died goats from vaccinated groups showed regression of gross JD lesions and regeneration of fat layer around visceral organs while "Sham-immunized" goats exhibited frank lesions. Vaccinated goats had higher protective CMI response and also higher antibody titer for the trial period as compared to "Sham immunized". Both vaccines also reduced shedding of MAP in feces significantly (P < .05). Though the two vaccines effectively restricted the severity of clinical symptoms of JD, however "Indigenous vaccine" was superior in many respects.
Singh
S V
SV
Veterinary Microbiology Laboratory, Animal Health Division, Central Institute for Research on Goats, Makhdoom, Farah, Mathura 281 122, India.
Singh
P K
PK
Singh
A V
AV
Sohal
J S
JS
Sharma
M C
MC
Prev Vet Med. 1999 Jun 11;40(3-4):179-92
10423773
Am Rev Respir Dis. 1987 Sep;136(3):575-9
2443047
Rev Sci Tech. 2005 Dec;24(3):1061-6
16642774
Vaccine. 2007 Oct 10;25(41):7102-10
17804124
J Clin Microbiol. 1984 Nov;20(5):966-71
6511878
Nature. 1996 Oct 31;383(6603):787-93
8893001
J Comp Pathol. 1994 Feb;110(2):185-94
8040384
Clin Diagn Lab Immunol. 2002 Nov;9(6):1367-71
12414776
Int J Infect Dis. 2009 Sep;13(5):e221-7
19233699
J Lab Clin Med. 1987 Jul;110(1):31-40
2439622
Tubercle. 1991 Jun;72(2):133-9
1949216
Vet Microbiol. 2009 Mar 2;134(3-4):375-82
18838235
Anal Biochem. 2002 Jul 1;306(1):79-82
12069417
J Am Vet Med Assoc. 1984 Apr 15;184(8):939-43
6715223
Vet Rec. 1996 Dec 21-28;139(25):624-7
9123788
Vet Microbiol. 2000 Dec 20;77(3-4):475-85
11118732
Vaccine. 2003 Jul 4;21(23):3101-9
12804836
Scand J Clin Lab Invest Suppl. 1968;97:7
5707208
Vet Rec. 1985 Apr 20;116(16):439-41
4002570
Microbiol Res. 2010 Feb 28;165(2):163-71
19442500
Tijdschr Diergeneeskd. 1984 Nov 15;109(22):905-16
6393423
Microb Pathog. 2003 Feb;34(2):81-90
12623276
Am J Vet Res. 1991 Aug;52(8):1197-200
1928899
Immunology. 1994 Feb;81(2):171-6
8157267
Bull Off Int Epizoot. 1967 May;68(1):743-8
5618594
Am J Vet Res. 1964 Jul;25:974-6
14266908
Br Vet J. 1982 Jul-Aug;138(4):321-31
7116121
Vet Rec. 1976 Jun 5;98(23):463
936464